• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗糖尿病药物与心力衰竭——对CARMELINA研究的回应

Anti-Diabetic Agents and Heart Failure - Response to the CARMELINA Study.

作者信息

Sano Motoaki

机构信息

Department of Cardiology, Keio University School of Medicine Tokyo Japan.

出版信息

Circ Rep. 2018 Dec 11;1(1):4-7. doi: 10.1253/circrep.CR-18-0011.

DOI:10.1253/circrep.CR-18-0011
PMID:33693068
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7925121/
Abstract

According to cardiovascular outcome trials, some anti-diabetic drugs can improve cardiovascular outcomes in patients with type 2 diabetes. Sodium glucose cotransporter 2 inhibitors (empagliflozin, canagliflozin, and dapagliflozin) have a strong preventive effect on both hospitalization for heart failure and the decline in kidney function in patients with type 2 diabetes, while glucagon-like peptide-1 receptor agonists, especially human glucagon-like peptide-1 receptor agonists (liraglutide, semaglutide, and albiglutide), suppress arteriosclerotic diseases (stroke and myocardial infarction). Using these medications in combination could possibly prevent both hospitalization for heart failure and arteriosclerotic events. Dipeptidyl peptidase 4 (DPP-4) inhibitors are preferentially used as add-on therapy for type 2 diabetes. Cardiovascular outcome trials conducted so far suggest that DPP-4 inhibitors (sitagliptin, alogliptin, and saxagliptin) do not promote arteriosclerotic disease, but there may be a difference between these drugs with regard to safety for heart failure. Previous cardiovascular outcome trials have mainly focused on type 2 diabetes patients with established cardiovascular disease. In contrast, the CARMELINA study investigated the cardiovascular safety of linagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes and kidney dysfunction.

摘要

根据心血管结局试验,一些抗糖尿病药物可改善2型糖尿病患者的心血管结局。钠-葡萄糖协同转运蛋白2抑制剂(恩格列净、卡格列净和达格列净)对2型糖尿病患者的心力衰竭住院和肾功能下降均有很强的预防作用,而胰高血糖素样肽-1受体激动剂,尤其是人胰高血糖素样肽-1受体激动剂(利拉鲁肽、司美格鲁肽和阿必鲁肽)可抑制动脉粥样硬化疾病(中风和心肌梗死)。联合使用这些药物可能预防心力衰竭住院和动脉粥样硬化事件。二肽基肽酶4(DPP-4)抑制剂优先用作2型糖尿病的附加治疗。迄今为止进行的心血管结局试验表明,DPP-4抑制剂(西格列汀、阿格列汀和沙格列汀)不会促进动脉粥样硬化疾病,但这些药物在心力衰竭安全性方面可能存在差异。以往的心血管结局试验主要关注已患有心血管疾病的2型糖尿病患者。相比之下,CARMELINA研究调查了DPP-4抑制剂利格列汀在2型糖尿病和肾功能不全患者中的心血管安全性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b9f/7925121/6aa7c9b99fdf/circrep-1-4-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b9f/7925121/8d96a945a3fe/circrep-1-4-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b9f/7925121/6aa7c9b99fdf/circrep-1-4-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b9f/7925121/8d96a945a3fe/circrep-1-4-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b9f/7925121/6aa7c9b99fdf/circrep-1-4-g002.jpg

相似文献

1
Anti-Diabetic Agents and Heart Failure - Response to the CARMELINA Study.抗糖尿病药物与心力衰竭——对CARMELINA研究的回应
Circ Rep. 2018 Dec 11;1(1):4-7. doi: 10.1253/circrep.CR-18-0011.
2
Cardiovascular outcome trials of glucose-lowering medications: an update.降糖药物心血管结局试验的更新。
Diabetologia. 2019 Mar;62(3):357-369. doi: 10.1007/s00125-018-4801-1. Epub 2019 Jan 3.
3
Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials.2 型糖尿病与肾脏:心血管结局试验的新视角。
Diabetes Obes Metab. 2019 Aug;21(8):1790-1800. doi: 10.1111/dom.13743. Epub 2019 May 2.
4
Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope.心力衰竭和 2 型糖尿病:从心血管结局试验中看到希望。
Diabetes Obes Metab. 2019 May;21(5):1081-1087. doi: 10.1111/dom.13629. Epub 2019 Feb 14.
5
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.胰高血糖素样肽-1 受体激动剂和二肽基肽酶-4 抑制剂的心血管作用和临床结局。
Circulation. 2017 Aug 29;136(9):849-870. doi: 10.1161/CIRCULATIONAHA.117.028136.
6
The kidney and cardiovascular outcome trials.肾脏和心血管结局试验。
J Diabetes. 2018 Feb;10(2):88-89. doi: 10.1111/1753-0407.12616.
7
Cardiovascular safety outcomes of new antidiabetic therapies.新型抗糖尿病疗法的心血管安全性结局
Am J Health Syst Pharm. 2017 Jul 1;74(13):970-976. doi: 10.2146/ajhp160279. Epub 2017 May 8.
8
Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?二肽基肽酶-4 抑制剂与 2 型糖尿病的心血管和肾脏疾病:我们从 CARMELINA 试验中学到了什么?
Diab Vasc Dis Res. 2019 Jul;16(4):303-309. doi: 10.1177/1479164119842339. Epub 2019 Apr 24.
9
The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.二肽基肽酶-4 抑制剂、胰高血糖素样肽-1 激动剂和钠-葡萄糖共转运蛋白 2 抑制剂的心血管安全性试验。
Trends Cardiovasc Med. 2017 Apr;27(3):194-202. doi: 10.1016/j.tcm.2017.01.009. Epub 2017 Jan 28.
10
Cardiovascular Protection with Anti-hyperglycemic Agents.抗高血糖药物的心血管保护作用。
Am J Cardiovasc Drugs. 2019 Jun;19(3):249-257. doi: 10.1007/s40256-019-00325-9.

引用本文的文献

1
Pericoronary adipose tissue: potential for pathological diagnosis and therapeutic applications.冠状动脉周围脂肪组织:病理诊断及治疗应用潜力
Cardiovasc Interv Ther. 2025 Apr 5. doi: 10.1007/s12928-025-01126-5.

本文引用的文献

1
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.利拉利汀对比安慰剂对伴有高心血管和肾脏风险的 2 型糖尿病成人患者主要心血管事件的影响:CARMELINA 随机临床试验。
JAMA. 2019 Jan 1;321(1):69-79. doi: 10.1001/jama.2018.18269.
2
Mechanism by which dipeptidyl peptidase-4 inhibitors increase the risk of heart failure and possible differences in heart failure risk.二肽基肽酶-4 抑制剂增加心力衰竭风险的机制及心力衰竭风险的可能差异。
J Cardiol. 2019 Jan;73(1):28-32. doi: 10.1016/j.jjcc.2018.07.004. Epub 2018 Oct 12.
3
Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo-controlled, double-blind clinical trials.
利格列汀治疗 2 型糖尿病患者的心率变化:安慰剂对照、双盲临床试验的亚分析。
J Diabetes Investig. 2018 May;9(3):638-641. doi: 10.1111/jdi.12726. Epub 2018 May 3.
4
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.SGLT-2 抑制剂与其他降血糖药物相关的心血管事件:CVD-REAL 2 研究。
J Am Coll Cardiol. 2018 Jun 12;71(23):2628-2639. doi: 10.1016/j.jacc.2018.03.009. Epub 2018 Mar 11.
5
A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.一类用于治疗心力衰竭的新型药物:钠-葡萄糖协同转运蛋白2抑制剂可降低交感神经过度活动。
J Cardiol. 2018 May;71(5):471-476. doi: 10.1016/j.jjcc.2017.12.004. Epub 2018 Feb 4.
6
Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α in Patients With Type 2 Diabetes.二肽基肽酶 4 抑制作用可刺激 2 型糖尿病患者远端肾小管钠排泄,并增加循环 SDF-1α。
Diabetes Care. 2017 Aug;40(8):1073-1081. doi: 10.2337/dc17-0061. Epub 2017 May 26.
7
Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.钠-葡萄糖协同转运蛋白2抑制剂的血流动力学效应
J Clin Med Res. 2017 Jun;9(6):457-460. doi: 10.14740/jocmr3011w. Epub 2017 Apr 26.
8
Diabetes, hypertension, and chronic kidney disease progression: role of DPP4.糖尿病、高血压和慢性肾脏病进展:DPP4 的作用。
Am J Physiol Renal Physiol. 2017 Apr 1;312(4):F661-F670. doi: 10.1152/ajprenal.00316.2016. Epub 2017 Jan 25.
9
Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys.钠-葡萄糖协同转运蛋白2抑制剂治疗期间血细胞比容升高表明糖尿病肾病肾小管间质功能恢复
J Clin Med Res. 2016 Dec;8(12):844-847. doi: 10.14740/jocmr2760w. Epub 2016 Oct 26.
10
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.西他列汀对 2 型糖尿病患者肾功能及相应心血管结局的影响:TECOS 研究结果。
Diabetes Care. 2016 Dec;39(12):2304-2310. doi: 10.2337/dc16-1415. Epub 2016 Oct 14.